ArticleCells2026
Cytoskeletal Protein 4.1R Inhibits BCR-Mediated B-Cell Activation by Restraining AKT1 Phosphorylation.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
B-cell receptor (BCR) is indispensable for B-cell responses, and its signaling relies on the rearrangement of cytoskeletal proteins. Cytoskeletal protein 4.1R has been previously implicated in the regulation of immune function. However, the specific role of 4.1R in BCR-mediated B-cell activation remains unknown. Here, we performed single-cell RNA (scRNA) sequencing on splenic B cells isolated from wild-type (WT) and 4.1R-knockout (4.1R-KO) mice to systematically characterize the functional contribution of 4.1R to B-cell biology. Transcriptomic analyses suggested a critical role for 4.1R in modulating BCR signaling. Ex vivo stimulation of primary B cells with anti-IgM demonstrated that 4.1R-KO B cells exhibited marked overactivation, hyperproliferation, and enhanced antibody secretion. Furthermore, unbiased phosphoproteomic profiling, identified sustained AKT1 phosphorylation as a key feature in 4.1R-KO B cells. Subsequent functional validation confirmed that 4.1R regulates BCR signaling by constraining AKT1 activation. Mechanistically, 4.1R rapidly colocalized with the coreceptor CD19 at the plasma membrane upon BCR engagement, and co-immunoprecipitation confirmed their physical interaction. Loss of 4.1R disrupted this interaction and resulted in sustained and amplified AKT1 phosphorylation (but not AKT2) in stimulated B cells. Collectively, our findings identify 4.1R as a novel negative regulator of BCR signaling that interacts with CD19 to constrain AKT1 activation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.